SICKLE CELL DISEASE
Anemia Management
English
Anemia Management
/assets/ct/79e1b14fff/images/syn_placeholder_sqr.png

Sickle Cell Disease

Anemia Management

A phase 1b/2 study of the efficacy and safety of combination hydroxyurea and dose-escalated erythropoietin for treatment of anemia in sickle cell disease (ACHiEvE-SCD). (opens new window)

Adeyemo TA, Kiriza N, Oluwole FT, Jelinek M, Jonassaint J, Oluwole O, Saber C, Philips BJ, Akinsanya OJD, Osunkalu VO, DeCastro LM, Novelli EM, Xu JZ

Source‎: Blood 2024;144(Suppl 1):178-9.

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. (opens new window)

el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.

Source‎: Acta Haematol 1995;94(3):128-34.

Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. (opens new window)

Little JA, McGowan VR, Kato GJ, Partovi KS, Feld JJ, Maric I, Martyr S, Taylor JG 6th, Machado RF, Heller T, Castro O, Gladwin MT.

Source‎: Haematologica 2006;91(8):1076-83.

Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease. (opens new window)

Tan TL, Ahmad H, Jhavar R, Patel R, Harrison C, Oteng-Ntim E.

Source‎: J Obstet Gynaecol 2007;27(1):82-3.